Combining BioAccord, our most capable MS detection platform, with ACQUITY Premier UPLC, our highest performance LC system, to demonstrate superior performance.
The worldwide coronavirus pandemic has changed the way that scientists and companies work. Learn how the Waters COVID-19 Innovation Response Team enabled the critical collaboration and pooling of expertise that enabled fast and safe vaccine development.
The development of biotherapeutics continues to accelerate with their potential to revolutionize disease treatment in areas not adequately addressed by small molecule therapeutics. However, the complexity of these macromolecules and the range of potential modification… Read more >
To ensure compliance success in a changing regulatory landscape, laboratories must continually adapt. Learn how the compliant-ready Waters BioAccord LC-MS platform helps biopharma address the additional compliance challenges posed by the field’s complex analytical instruments.
During 2020, we collaborated with many of our customers to develop targeted liquid chromatography–mass spectrometry/mass spectrometry (LC-MS/MS) methods to detect SARS-CoV-2 (the virus that causes COVID-19) from biological samples. However, the combination of the biological… Read more >
Oligonucleotides, or short strands of DNA or RNA, continue to increase in popularity. In addition to their essential role as primers and probes in the expanding clinical DNA testing and diagnostics market, they’re also seeing… Read more >
As scientific advances continue to carry researchers into new arenas, it is vital that technology evolves in tandem. At Waters, we understand that it is only by leveraging fit-for-purpose technologies that researchers are able to… Read more >
In this series, we review considerations for keeping your lab at the forefront of science. As you adjust to living and working in a pandemic and anticipate future global and geopolitical events, Waters remains dedicated… Read more >
Many years ago, I was hired by a biopharma company to develop analytical methods for therapeutic oligonucleotides. When a new colleague warned me about sample loss on LC columns I looked at him with skepticism.… Read more >
In January of 2018, Waters kicked off its global Bioharmonization campaign with a blog post and video release, laying out a vision for how the Biopharmaceutical industry can achieve accelerated development and improved quality while… Read more >
